Recent Research Analysts’ Ratings Changes for MiMedx Group (MDXG)

MiMedx Group (NASDAQ: MDXG) has recently received a number of price target changes and ratings updates:

• 12/22/2025 – MiMedx Group had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/17/2025 – MiMedx Group had its price target lowered by analysts at Mizuho from $12.00 to $10.00. They now have an “outperform” rating on the stock.
• 12/15/2025 – MiMedx Group had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – MiMedx Group had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – MiMedx Group had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – MiMedx Group had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – MiMedx Group had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/2/2025 – MiMedx Group was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.

Insiders Place Their Bets

In related news, insider Kimberly Maersk-Moller sold 58,300 shares of the company’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $7.42, for a total value of $432,586.00. Following the completion of the transaction, the insider directly owned 236,982 shares in the company, valued at approximately $1,758,406.44. The trade was a 19.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.70% of the stock is owned by corporate insiders.

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.